Retrospective analysis finds thrombocytopenia correlates with major bleeding and thrombotic events in cancer-associated thrombosis patients, suggesting careful management is crucial.
Key Points
Thrombocytopenia significantly increases the risk of major bleeding in patients with cancer-associated thrombosis.
The cumulative incidence of major bleeding at one year was found to be 12.0%, indicating substantial risks for these patients.
Incorporating time-varying thrombocytopenia into clinical strategies can help manage complications associated with cancer treatment.
The study highlights the importance of careful anticoagulation therapy tailored for patients with fluctuating platelet counts.